NASDAQ:CERE Cerevel Therapeutics (CERE) Stock Price, News & Analysis $40.96 +0.66 (+1.64%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$40.05▼$41.0250-Day Range$38.96▼$42.7552-Week Range$19.59▼$43.59Volume1.55 million shsAverage Volume1.56 million shsMarket Capitalization$7.46 billionP/E RatioN/ADividend YieldN/APrice Target$42.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get Cerevel Therapeutics alerts: Email Address Cerevel Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.11 Rating ScoreUpside/Downside4.2% Upside$42.67 Price TargetShort InterestHealthy7.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 11 Articles This WeekInsider TradingSelling Shares$3.13 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.59) to ($2.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.23 out of 5 starsMedical Sector861st out of 879 stocksPharmaceutical Preparations Industry411th out of 417 stocks 1.1 Analyst's Opinion Consensus RatingCerevel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 1 buy rating, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageCerevel Therapeutics has received no research coverage in the past 90 days.Read more about Cerevel Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.27% of the float of Cerevel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCerevel Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Cerevel Therapeutics has recently decreased by 12.88%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCerevel Therapeutics does not currently pay a dividend.Dividend GrowthCerevel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERE. Previous Next 2.1 News and Social Media Coverage News SentimentCerevel Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Cerevel Therapeutics this week, compared to 4 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,134,500.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Cerevel Therapeutics is held by insiders.Percentage Held by Institutions87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cerevel Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.59) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerevel Therapeutics is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerevel Therapeutics is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerevel Therapeutics has a P/B Ratio of 11.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cerevel Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… and people laughed at me.Click here for my urgent election update. About Cerevel Therapeutics Stock (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More CERE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERE Stock News HeadlinesJuly 4, 2024 | insidertrades.comCerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director N Anthony Coles Sells 25,000 SharesJuly 5 at 9:36 AM | americanbankingnews.comCerevel Therapeutics (NASDAQ:CERE) Sees Unusually-High Trading VolumeJuly 8, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on August 19.July 5 at 5:02 AM | americanbankingnews.comN Anthony Coles Sells 25,000 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) StockJuly 4, 2024 | americanbankingnews.comTraders Buy High Volume of Call Options on Cerevel Therapeutics (NASDAQ:CERE)June 27, 2024 | insidermonkey.comWhy Is Cerevel Therapeutics Holdings, Inc. (CERE) One of the Best Healthcare Stocks to Buy Under $50?June 25, 2024 | globenewswire.comCEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Urged to Contact the FirmJune 22, 2024 | globenewswire.comCEREVEL (NASDAQ:CERE) INVESTOR ALERT: Cerevel's $45 Per Share Offer is Being Investigated by BFA Law, Shareholders are Encouraged to Contact the FirmJuly 8, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on August 19.June 20, 2024 | prnewswire.comCERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law FirmJune 20, 2024 | globenewswire.comCEREVEL INVESTOR REMINDER: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law about Continuing Investigation into the OfferJune 18, 2024 | businesswire.comCERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law FirmJune 18, 2024 | globenewswire.comCEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoing Investigation into the Deal PriceJune 13, 2024 | globenewswire.comCEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Encourages Investors to Contact the FirmJune 11, 2024 | globenewswire.comCEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urges Shareholders to Contact the Firm About Your RightsJune 11, 2024 | globenewswire.comCEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urges Shareholders to Contact the Firm About Your RightsJune 8, 2024 | globenewswire.comCEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into the $45 Merger Offer, Contact the Firm About Your RightsJune 5, 2024 | globenewswire.comCEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law about the $45 Merger Offer from AbbVieSee More Headlines Receive CERE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/07/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryCoal & Consumable Fuels Current SymbolNASDAQ:CERE CUSIP15677310 CIK767884 Webceres.net Phone844-304-2048FaxN/AEmployees334Year FoundedN/APrice Target and Rating Average Stock Price Target$42.67 High Stock Price Target$45.00 Low Stock Price Target$31.00 Potential Upside/Downside+4.2%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-432,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-98.94% Return on Assets-45.07% Debt Debt-to-Equity Ratio0.60 Current Ratio10.22 Quick Ratio10.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.71 per share Price / Book11.04Miscellaneous Outstanding Shares182,200,000Free Float172,903,000Market Cap$7.46 billion OptionableOptionable Beta1.40 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. N. Anthony Coles Jr. (Age 64)M.P.H., Executive Chairman Comp: $1.14MMr. Mark Bodenrader (Age 51)VP of Finance & Chief Accounting Officer Comp: $496.17kDr. John J. Renger Ph.D. (Age 55)Chief Scientific Officer Comp: $779.75kDr. Ramiro Sanchez M.D. (Age 63)Chief Medical Officer Comp: $805.13kMr. Ronald C. Renaud Jr. (Age 55)M.B.A., President, CEO & Director Dr. Susan Altschuller M.B.A. (Age 42)Ph.D., Chief Financial Officer Mr. Matthew CalistriVice President of Investor RelationsMr. Scott M. Akamine J.D. (Age 39)Chief Legal Officer & Corporate Secretary Comp: $444.74kMr. Kenneth A. DiPietro (Age 65)Chief Human Resources Officer Ms. Kathleen Tregoning M.A. (Age 53)Chief Corporate Affairs Officer Comp: $600.79kMore ExecutivesKey CompetitorsWarrior Met CoalNYSE:HCCCNX ResourcesNYSE:CNXArch ResourcesNYSE:ARCHHallador EnergyNASDAQ:HNRGTeva Pharmaceutical IndustriesNYSE:TEVAView All CompetitorsInsiders & InstitutionsThurston Springer Miller Herd & Titak Inc.Bought 3,107 shares on 7/5/2024Ownership: 0.002%N Anthony ColesSold 25,000 sharesTotal: $1.03 M ($41.18/share)Walleye Trading LLCBought 500 shares on 5/17/2024Ownership: 0.000%Comerica BankSold 69,207 shares on 5/17/2024Ownership: 0.000%Blackstone Inc.Bought 20,651 shares on 5/16/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions CERE Stock Analysis - Frequently Asked Questions How have CERE shares performed this year? Cerevel Therapeutics' stock was trading at $42.40 at the beginning of the year. Since then, CERE shares have decreased by 3.4% and is now trading at $40.96. View the best growth stocks for 2024 here. How were Cerevel Therapeutics' earnings last quarter? Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) posted its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.12. Who are Cerevel Therapeutics' major shareholders? Cerevel Therapeutics' top institutional shareholders include Thurston Springer Miller Herd & Titak Inc.. Insiders that own company stock include Bain Capital Investors Llc, Perceptive Advisors Llc, Ronald C Renaud Jr, N Anthony Coles, Kenneth Dipietro, Paul D Burgess, Mark Bodenrader, Susan Altschuller, Ramiro Sanchez, John Renger, Scott Akamine, Abraham Ceesay and Deval L Patrick. View institutional ownership trends. How do I buy shares of Cerevel Therapeutics? Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cerevel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO) and Hess (HES). This page (NASDAQ:CERE) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerevel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERE Stock Alerts